Add-on Acquisition • Life Science

DifGen Acquires KriGen

On December 11, 2023, DifGen acquired life science company KriGen

Acquisition Context

This is DifGen’s 2nd transaction in the Life Science sector.
This is DifGen’s 2nd transaction in the United States.
This is DifGen’s 1st transaction in North Carolina.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	December 11, 2023
Target	KriGen
Sector	Life Science
Buyer(s)	DifGen
Deal Type	Add-on Acquisition

Target Company

KriGen

Lillington, North Carolina, United States

KriGen is a fully integrated sterile drug product manufacturer with the capability to manufacture a wide range of parenteral products including LVP bags (both Aseptic & Terminally Sterilized), PFS, Microspheres& complex Long Acting Injectables. KriGen is based in Lillington, North Carolina.

Explore More Deals

Browse All 215,130 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

DifGen

Princeton, New Jersey, United States

Category	Company
Sector	Life Science

DESCRIPTION

DifGen is a pharmaceutical company with a primary focus on developing complex high barrier to entry Generics and Specialty Pharmaceutical products that would help increase accessibility to high-quality medication thereby leading to the creation of next-generation healthy communities. DifGen is based in Princeton, New Jersey.

Deal Context for Buyer	#
Overall	2 of 2
Sector: Life Science	2 of 2
Type: Add-on Acquisition	1 of 1
State: North Carolina	1 of 1
Country: United States	2 of 2
Year: 2023	2 of 2

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2023-04-24	Aveva Miramar, Florida, United States AVEVA is a transdermal drug delivery provider. The company provides pharmaceutical partners with fully integrated, controlled-release transdermal products that fulfill unmet market needs or supply high-quality, affordable brand equivalents. Aveva was founded in 1991 and is based in Miramar, Florida.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2023-04-24

Aveva

Miramar, Florida, United States

AVEVA is a transdermal drug delivery provider. The company provides pharmaceutical partners with fully integrated, controlled-release transdermal products that fulfill unmet market needs or supply high-quality, affordable brand equivalents. Aveva was founded in 1991 and is based in Miramar, Florida.

Buy

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - North Carolina M&A - United States M&A - 2023 M&A